Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

Launched by UNIVERSITY OF WISCONSIN, MADISON · Dec 21, 2007

Keywords

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Metastatic hormone refractory prostate cancer.
• • Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1.
• • testosterone \<50ng/dL. Patients must continue primary androgen deprivation with an LHRH analogue if they have not undergone orchiectomy.
• • Progressive disease after androgen deprivation.
• Exclusion Criteria:
• • Patients whose clinical condition would make chemotherapy clearly indicated.
• • Patients who have received systemic chemotherapy for the treatment of metastatic disease.
• • Peripheral neuropathy \> Grade 1
• • Prior anti-angiogenic therapy, including thalidomide.
• • Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure or radiation within 4 weeks prior to study entry.
• • Patients who have received radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.
• • Patients with known brain metastases or history of brain metastases.
• • History of stroke within 6 months of treatment or other significant neurological limitations.
• • Patients who have received more than 2 prior investigational treatments.
• • Uncontrolled intercurrent illness
• • Patients with a history of a myocardial infarction within the prior 6 months or, hospitalizations for decompensated congestive heart failure within the prior 6 months, or history of significant / symptomatic cardiac arrhythmias